Furthermore, additional studies are needed to determine whether G6PD activity, when combined with other non-invasive biomarkers such as PSA, ALP and osteopontin, can improve the accuracy of predicting bone metastasis in prostate cancer patients. The gene discussed is G6PD; the disease is prostate carcinoma.